Unlike previous studies, we used cardiomyocyte-specific, not global, Pgam5-KO mice, which may explain why, after STZ administration, we did not observe obvious improvement in diabetes-related end points such as fasting plasma glucose, serum cholesterol, body weight, and glucose tolerance in these animals. This evidence concerns the gene PGAM5 and diabetes mellitus.